Abstract
Dupilumab is a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. It is the first biologic agent to demonstrate efficacy in treating moderate-to-severe refractory atopic dermatitis [1, 2]. Although dupilumab provides promise for the treatment of atopic and allergic conditions, clinicians should take into account its novelty and the potential for unexpected adverse events. We present a patient who developed Sézary syndrome following the initiation of dupilumab.
Original language | English (US) |
---|---|
Article number | 17 |
Journal | Dermatology online journal |
Volume | 26 |
Issue number | 4 |
State | Published - Apr 2020 |
Keywords
- Atopic dermatitis
- Cutaneous T cell lymphoma
- Dupilumab
- Erythroderma
- Sézary syndrome
ASJC Scopus subject areas
- Dermatology